Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05498792Early Phase 1Recruiting

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Role: collaborator

NCT03727789Phase 1Terminated

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

Role: collaborator

NCT01905228Phase 1Completed

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

Role: lead

NCT02931110Phase 1Terminated

Study of IV CBL0137 in Previously Treated Hematological Subjects

Role: lead

All 4 trials loaded